| Year |
Citation |
Score |
| 2021 |
Manohar PM, Davidson NE. Updates in endocrine therapy for metastatic breast cancer. Cancer Biology & Medicine. PMID 34609096 DOI: 10.20892/j.issn.2095-3941.2021.0255 |
0.342 |
|
| 2021 |
Yung RL, Davidson NE. Optimal adjuvant endocrine therapy for breast cancer. The Lancet. Oncology. 22: 1357-1358. PMID 34543612 DOI: 10.1016/S1470-2045(21)00420-4 |
0.361 |
|
| 2021 |
Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101374. PMID 34324366 DOI: 10.1200/JCO.21.01374 |
0.319 |
|
| 2021 |
Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, ... ... Davidson NE, et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer Discovery. PMID 34183353 DOI: 10.1158/2159-8290.CD-20-1647 |
0.34 |
|
| 2021 |
Vinayak S, Davidson NE. Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought? Journal of the National Cancer Institute. PMID 34101813 DOI: 10.1093/jnci/djab092 |
0.34 |
|
| 2020 |
Reis-Filho JS, Davidson NE. Ki67 Assessment in Breast Cancer: Are We There yet? Journal of the National Cancer Institute. PMID 33369665 DOI: 10.1093/jnci/djaa202 |
0.379 |
|
| 2020 |
Hunter NB, Kilgore MR, Davidson NE. The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32859655 DOI: 10.1158/1078-0432.CCR-20-2451 |
0.351 |
|
| 2020 |
Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, Gralow JR, et al. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. Jama Oncology. PMID 31917424 DOI: 10.1001/Jamaoncol.2019.5559 |
0.333 |
|
| 2020 |
Guenthoer J, Jenkins IC, Thompson B, Tang MC, Davidson NE, Ashley RL, Li CI, Hsu L, Porter PL. Abstract P6-05-03: Exogenous steroid hormone exposure and the biology of lobular breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-05-03 |
0.337 |
|
| 2020 |
King TA, Liu MC, McClure MB, Hinoue T, Kelly BJ, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Rezk S, Garrett AL, Balko JM, Parker JS, Park BH, ... ... Davidson NE, et al. Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs3-08 |
0.351 |
|
| 2019 |
Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, Ke B, Zhu C, Deng R, Tang J, Yao J, Chu YY, Zhao X, Han Y, Hou J, ... ... Davidson NE, et al. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nature Communications. 10: 5114. PMID 31704972 DOI: 10.1038/s41467-019-13105-5 |
0.324 |
|
| 2019 |
Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, Floyd JD, Garber JE, Hofstatter EW, Khan SA, Katapodi MC, Pruthi S, Raab R, Runowicz CD, Somerfield MR. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901472. PMID 31479306 DOI: 10.1200/Jco.19.01472 |
0.359 |
|
| 2019 |
Cheung KJ, Davidson NE. Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era. Journal of the National Cancer Institute. PMID 30698728 DOI: 10.1093/jnci/djy203 |
0.331 |
|
| 2018 |
Giordano SH, Temin S, Davidson NE. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. Journal of Oncology Practice. JOP1800290. PMID 29989839 DOI: 10.1200/JOP.18.00290 |
0.318 |
|
| 2018 |
Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, Modi S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018792697. PMID 29939838 DOI: 10.1200/JCO.2018.79.2697 |
0.343 |
|
| 2018 |
Cao C, Wu H, Vasilatos SN, Chandran U, Qin Y, Wan Y, Oesterreich S, Davidson NE, Huang Y. HDAC5-LSD1 Axis Regulates Antineoplastic Effect of Natural HDAC Inhibitor Sulforaphane in Human Breast Cancer Cells. International Journal of Cancer. PMID 29633255 DOI: 10.1002/ijc.31419 |
0.336 |
|
| 2018 |
Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali S, Ross J, Leyland-Jones B, Young B, ... ... Davidson NE, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29360925 DOI: 10.1093/Annonc/Mdy025 |
0.361 |
|
| 2018 |
Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F, Boddington C, Bogaerts J, Bonadonna G, Bradley R, Brain E, Braybrooke J, Broet P, Bryant J, ... ... Davidson N, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials Lancet Oncology. 19: 27-39. PMID 29242041 DOI: 10.1016/S1470-2045(17)30777-5 |
0.349 |
|
| 2018 |
Verma N, Harding D, Mohammadi A, Goldstein LJ, Gilmore HL, Feldman MD, Tomaszewski J, Basavanhally A, Lloyd M, Fu P, Ganesan S, Davidson NE, Madabhushi A, Monaco J. Image-based risk score to predict recurrence of ER+ breast cancer in ECOG-ACRIN Cancer Research Group E2197. Journal of Clinical Oncology. 36: 540-540. DOI: 10.1200/Jco.2018.36.15_Suppl.540 |
0.373 |
|
| 2018 |
Badve S, Wang V, Willis S, Leyland-Jones B, Gokmen-Polar Y, Shulman L, Martino S, Sparano J, Davidson N, Goldstein L, Buechler S. Abstract P1-06-08: Independent validation of EarlyR gene signature in E2197: A randomized clinical trial comparing doxorubicin plus docetaxel to doxorubicin plus cyclophosphamide as adjuvant chemotherapy in breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P1-06-08 |
0.333 |
|
| 2018 |
Priedigkeit N, Vareslija D, Basudan A, Watters R, Lucas P, Davidson N, Blohmer J, Denkert C, Machleidt A, Heppner B, Brufsky A, Oesterreich S, Young L, Lee A. Abstract GS2-03: Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Gs2-03 |
0.385 |
|
| 2018 |
Woodcock C, Woodcock S, Salvatore S, Davidson N, Huang Y, Freeman B. Electrophilic Nitro‐oleic Acid Inhibits Triple Negative Breast Cancer Cell Migration via Suppression of NF‐kB activity The Faseb Journal. 31. DOI: 10.1096/Fasebj.31.1_Supplement.934.1 |
0.34 |
|
| 2017 |
Woodcock CC, Huang Y, Woodcock SR, Salvatore SR, Singh B, Golin-Bisello F, Davidson NE, Neumann C, Freeman BA, Wendell SG. Nitro-fatty acid inhibition of triple negative breast cancer cell viability, migration, invasion and tumor growth. The Journal of Biological Chemistry. PMID 29158255 DOI: 10.1074/Jbc.M117.814368 |
0.313 |
|
| 2017 |
Stanton SE, Davidson NE. Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer? Nature Reviews. Clinical Oncology. PMID 28786414 DOI: 10.1038/nrclinonc.2017.125 |
0.395 |
|
| 2017 |
Chen L, Vasilatos SN, Qin Y, Katz TA, Cao C, Wu H, Tasdemir N, Levine KM, Oesterreich S, Davidson NE, Huang Y. Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. Oncotarget. PMID 28753574 DOI: 10.18632/oncotarget.19387 |
0.384 |
|
| 2017 |
Bahreini A, Li Z, Wang P, Levine KM, Tasdemir N, Cao L, Weir HM, Puhalla SL, Davidson NE, Stern AM, Chu D, Park BH, Lee AV, Oesterreich S. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Research : Bcr. 19: 60. PMID 28535794 DOI: 10.1186/S13058-017-0851-4 |
0.328 |
|
| 2017 |
Gadi VK, Davidson NE. Practical Approach to Triple-Negative Breast Cancer. Journal of Oncology Practice. 13: 293-300. PMID 28489980 DOI: 10.1200/JOP.2017.022632 |
0.392 |
|
| 2017 |
Specht JM, Davidson NE. Optimal duration of trastuzumab for early HER2-positive breast cancer. Lancet (London, England). PMID 28215659 DOI: 10.1016/S0140-6736(17)30322-7 |
0.358 |
|
| 2017 |
Samanta SK, Sehrawat A, Kim SH, Hahm ER, Shuai Y, Roy R, Pore SK, Singh KB, Christner SM, Beumer JH, Davidson NE, Singh SV. Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A. Journal of the National Cancer Institute. 109. PMID 28040797 DOI: 10.1093/jnci/djw293 |
0.385 |
|
| 2017 |
Farrugia D, Landmann A, McAuliffe P, Diego E, Johnson R, Bonaventura M, Soran A, Dabbs D, Clark B, Lembersky B, Puhalla S, Brufsky A, Jankowitz R, Davidson N, Ahrendt G, et al. Abstract P6-09-14: Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-09-14 |
0.349 |
|
| 2017 |
Hartmaier RJ, Priedigkeit N, Goldberg ME, Suh J, Ali S, Ross J, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Bahreini A, Puhalla SL, Oesterreich S, ... ... Davidson NE, et al. Abstract 421: Comprehensive genomic analysis of metastatic breast cancers revealsESR1fusions as a recurrent mechanism of endocrine therapy resistance Cancer Research. 77: 421-421. DOI: 10.1158/1538-7445.Am2017-421 |
0.363 |
|
| 2017 |
Woodcock CS, Woodcock SR, Salvatore SR, Singh B, Golin-Bisello F, Davidson NE, Huang Y, Wendell SG, Freeman BA. Selective Inhibition of Triple Negative Breast Cancer Cell Mobility and Viability by Nitro-Oleic Acid Free Radical Biology and Medicine. 112: 99. DOI: 10.1016/J.Freeradbiomed.2017.10.148 |
0.319 |
|
| 2016 |
Huang Y, Davidson NE. Targeting tumorigenicity of breast cancer stem-like cells using combination epigenetic therapy: something old and something new. Journal of Thoracic Disease. 8: 2971-2974. PMID 28066560 DOI: 10.21037/jtd.2016.11.18 |
0.328 |
|
| 2016 |
Connolly R, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater S, Powers P, Wolff AC, Fetting JH, Brufsky AM, Piekarz R, Ahuja N, Laird PW, Shen H, ... ... Davidson NE, et al. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27979916 DOI: 10.1158/1078-0432.Ccr-16-1729 |
0.395 |
|
| 2016 |
Jankowitz RC, Oesterreich S, Lee AV, Davidson NE. New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and other Targeted Therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27979914 DOI: 10.1158/1078-0432.CCR-16-0591 |
0.36 |
|
| 2016 |
Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, et al. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. Jama Oncology. PMID 27926948 DOI: 10.1001/Jamaoncol.2016.5630 |
0.345 |
|
| 2016 |
Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Yoshizawa CN, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, et al. The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814. International Journal of Radiation Oncology, Biology, Physics. 96: S146. PMID 27675638 DOI: 10.1016/J.Ijrobp.2016.06.354 |
0.31 |
|
| 2016 |
Brufsky AM, Davidson NE. Multi-parametric genomic assays for breast cancer: Time for the next generation? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27521446 DOI: 10.1158/1078-0432.CCR-16-1513 |
0.37 |
|
| 2016 |
Puhalla SL, Davidson NE. Breast cancer: The 21-gene recurrence score - biology remains at the forefront. Nature Reviews. Clinical Oncology. PMID 27296295 DOI: 10.1038/nrclinonc.2016.98 |
0.37 |
|
| 2016 |
Cao C, Vasilatos SN, Bhargava R, Fine JL, Oesterreich S, Davidson NE, Huang Y. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression. Oncogene. PMID 27212032 DOI: 10.1038/onc.2016.186 |
0.31 |
|
| 2016 |
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 1689-701. PMID 26884586 DOI: 10.1200/JCO.2015.65.9573 |
0.341 |
|
| 2016 |
Davidson NE. Conquering Metastatic Breast Cancer. Journal of Oncology Practice / American Society of Clinical Oncology. 12: 11-2. PMID 26759459 DOI: 10.1200/JOP.2015.009167 |
0.397 |
|
| 2016 |
Dowsett M, Lønning PE, Davidson NE. Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 1580-3. PMID 26729430 DOI: 10.1200/JCO.2015.62.3728 |
0.327 |
|
| 2016 |
Farrugia DJ, Landmann A, Diego E, McAuliffe PF, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Clark B, Puhalla S, Brufsky A, Jankowitz RC, Lembersky BC, Davidson NE, Ahrendt GM, et al. Mitotic index to predict breast cancer recurrence after neoadjuvant systemic therapy. Journal of Clinical Oncology. 34: e23265-e23265. DOI: 10.1200/JCO.2016.34.15_suppl.e23265 |
0.35 |
|
| 2016 |
Landmann A, Farrugia DJ, Diego E, Bonaventura M, Soran A, Johnson R, Dabbs DJ, Clark B, Brufsky A, Davidson NE, Lembersky BC, Jankowitz RC, Puhalla S, Ahrendt GM, McAuliffe PF, et al. HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors? Journal of Clinical Oncology. 34: 612-612. DOI: 10.1200/JCO.2016.34.15_SUPPL.612 |
0.362 |
|
| 2016 |
Landmann A, Farrugia DJ, Diego E, Soran A, Johnson R, Bonaventura M, Dabbs DJ, Clark B, Brufsky A, Davidson NE, Lembersky BC, Jankowitz RC, Puhalla S, Ahrendt GM, McAuliffe PF, et al. Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease? Journal of Clinical Oncology. 34: 580-580. DOI: 10.1200/JCO.2016.34.15_suppl.580 |
0.317 |
|
| 2016 |
Jankowitz R, McAuliffe P, Sikora M, Butler L, Ahrendt G, Johnson R, Diego E, Bonaventura M, Puhalla S, Lembersky B, Clark B, Brufsky A, Kurland B, Davidson N, Dabbs D, et al. Abstract P3-05-14: A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-05-14 |
0.336 |
|
| 2016 |
Bhargava R, Davidson NE. "Take two"? The role of second opinions for breast biopsy specimens Bmj (Online). 353. DOI: 10.1136/bmj.i3256 |
0.31 |
|
| 2015 |
Schneider BP, O'Neill A, Shen F, Sledge GW, Thor AD, Kahanic SP, Zander PJ, Davidson NE. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). British Journal of Cancer. PMID 26625004 DOI: 10.1038/bjc.2015.405 |
0.38 |
|
| 2015 |
Mathew A, Davidson NE. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Breast (Edinburgh, Scotland). PMID 26255743 DOI: 10.1016/j.breast.2015.07.027 |
0.312 |
|
| 2015 |
Liao S, Hartmaier RJ, McGuire KP, Puhalla SL, Luthra S, Chandran UR, Ma T, Bhargava R, Modugno F, Davidson NE, Benz S, Lee AV, Tseng GC, Oesterreich S. The molecular landscape of premenopausal breast cancer. Breast Cancer Research : Bcr. 17: 104. PMID 26251034 DOI: 10.1186/s13058-015-0618-8 |
0.338 |
|
| 2015 |
Nayak SR, Harrington E, Boone D, Hartmaier R, Chen J, Pathiraja TN, Cooper KL, Fine JL, Sanfilippo J, Davidson NE, Lee AV, Dabbs D, Oesterreich S. A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. Hormones & Cancer. PMID 26113056 DOI: 10.1007/S12672-015-0230-5 |
0.353 |
|
| 2015 |
Willis S, De P, Dey N, Long B, Young B, Sparano JA, Wang V, Davidson NE, Leyland-Jones BR. Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene. 4: 129-41. PMID 26005638 DOI: 10.1016/j.mgene.2015.04.002 |
0.361 |
|
| 2015 |
Reeder A, Attar M, Nazario L, Bathula C, Zhang A, Hochbaum D, Roy E, Cooper KL, Oesterreich S, Davidson NE, Neumann CA, Flint MS. Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage. British Journal of Cancer. 112: 1461-70. PMID 25880007 DOI: 10.1038/Bjc.2015.133 |
0.312 |
|
| 2015 |
Lee AV, Oesterreich S, Davidson NE. Mcf-7 cells-changing the course of breast cancer research and care for 45 years. Journal of the National Cancer Institute. 107. PMID 25828948 DOI: 10.1093/jnci/djv073 |
0.375 |
|
| 2015 |
Mathew A, Brufsky AM, Davidson NE. Can circulating tumor cells predict resistance in metastatic breast cancer? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2421-3. PMID 25645864 DOI: 10.1158/1078-0432.CCR-14-2967 |
0.329 |
|
| 2015 |
Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, et al. Adjuvant ovarian suppression in premenopausal breast cancer. The New England Journal of Medicine. 372: 436-46. PMID 25495490 DOI: 10.1056/NEJMoa1412379 |
0.375 |
|
| 2015 |
Puhalla S, Wang P, Bahreini A, Gyanchandani R, Ambros TF, Hartmaier RJ, Kurland BF, Lucas PC, Trejo Bittar HE, Hamilton RL, Mathew A, Leone JP, Davidson NE, Weiss KR, Watters RJ, et al. Detection and functional analysis of estrogen receptor mutations (ESR1-mut) in patients with metastatic breast cancer (MBC). Journal of Clinical Oncology. 33: 554-554. DOI: 10.1200/Jco.2015.33.15_Suppl.554 |
0.312 |
|
| 2015 |
Pahuja S, McGuire K, Davidson N, Brufsky A, Rastogi P, Jankowitz R, Lembersky B, Puhalla S. Abstract P3-11-10: Response to subsequent therapies after failure to achieve pathologic complete response (pCR) after neo-adjuvant chemotherapy (NAC) in patients (pts) with triple negative breast cancer (TNBC) Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-11-10 |
0.316 |
|
| 2015 |
Woodcock C, Woodcock S, Davidson N, Huang Y, Freeman B. Electrophilic Nitroalkenes Cause Degradation of NFκB RelA Protein in Triple Negative Breast Cancer Cells The Faseb Journal. 29. DOI: 10.1096/FASEBJ.29.1_SUPPLEMENT.945.8 |
0.361 |
|
| 2014 |
Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3744-52. PMID 25332249 DOI: 10.1200/JCO.2014.55.5730 |
0.389 |
|
| 2014 |
Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3307-29. PMID 25185096 DOI: 10.1200/Jco.2014.56.7479 |
0.335 |
|
| 2014 |
Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2959-66. PMID 25071121 DOI: 10.1200/Jco.2013.55.0491 |
0.323 |
|
| 2014 |
Katz TA, Huang Y, Davidson NE, Jankowitz RC. Epigenetic reprogramming in breast cancer: from new targets to new therapies. Annals of Medicine. 46: 397-408. PMID 25058177 DOI: 10.3109/07853890.2014.923740 |
0.403 |
|
| 2014 |
Zhou Z, Qiao JX, Shetty A, Wu G, Huang Y, Davidson NE, Wan Y. Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cellular and Molecular Life Sciences : Cmls. 71: 1549. PMID 25031550 DOI: 10.1007/S00018-013-1376-3 |
0.358 |
|
| 2014 |
Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE, Huang Y. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. Breast Cancer Research and Treatment. 146: 99-108. PMID 24924415 DOI: 10.1007/s10549-014-3012-9 |
0.367 |
|
| 2014 |
Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2078-99. PMID 24799465 DOI: 10.1200/JCO.2013.54.0948 |
0.318 |
|
| 2014 |
Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, ... Davidson NE, et al. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Science Translational Medicine. 6: 229ra41. PMID 24670685 DOI: 10.1126/Scitranslmed.3008326 |
0.327 |
|
| 2014 |
Davidson N, Camburn T, Keary I, Houghton D. Substituting Doxorubicin with nonpegylated liposomal Doxorubicin for the treatment of early breast cancer: results of a retrospective study. International Journal of Breast Cancer. 2014: 984067. PMID 24527216 DOI: 10.1155/2014/984067 |
0.374 |
|
| 2014 |
Palmieri C, Misra V, Januszewski A, Yosef H, Ashford R, Keary I, Davidson N. Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer. Clinical Breast Cancer. 14: 85-93. PMID 24325950 DOI: 10.1016/j.clbc.2013.10.011 |
0.347 |
|
| 2014 |
van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg DH, Donovan HS, Thurston RC, Morse JQ, Nutt S, Rechis R. Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 22: 937-45. PMID 24271937 DOI: 10.1007/S00520-013-2041-Y |
0.331 |
|
| 2014 |
Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 - Positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 Journal of Clinical Oncology. 32: 3744-3752. DOI: 10.1200/JCO.2014.55.5730 2014 |
0.306 |
|
| 2014 |
Connolly RM, Jankowitz RC, Zahnow CA, Zhang Z, Rudek MA, Slater S, Powers P, Jeter S, Brufsky A, Piekarz R, Herman JG, Ahuja N, Somlo G, Garcia AA, Baylin S, ... Davidson NE, et al. Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer. Journal of Clinical Oncology. 32: 569-569. DOI: 10.1200/Jco.2014.32.15_Suppl.569 |
0.349 |
|
| 2014 |
Woodcock C, Katz T, Davidson N, Freeman B, Huang Y. Therapeutic actions of electrophilic nitroalkenes via inhibition of the NFκB pathway in triple negative breast cancer Nitric Oxide. 42: 106. DOI: 10.1016/J.Niox.2014.09.027 |
0.368 |
|
| 2014 |
Lee AV, Oesterreich S, Davidson NE. The Molecular Biology of Breast Cancer The Molecular Basis of Cancer: Fourth Edition. 523-530.e3. DOI: 10.1016/B978-1-4557-4066-6.00036-6 |
0.375 |
|
| 2013 |
Jankowitz RC, Davidson NE. Adjuvant endocrine therapy for breast cancer: how long is long enough? Oncology (Williston Park, N.Y.). 27: 1210-6, 1224. PMID 24624537 |
0.368 |
|
| 2013 |
Oesterreich S, Davidson NE. The search for ESR1 mutations in breast cancer. Nature Genetics. 45: 1415-6. PMID 24270445 DOI: 10.1038/ng.2831 |
0.337 |
|
| 2013 |
Sharma D, Davidson NE. Obesity and breast cancer: a multipartite connection. Journal of Mammary Gland Biology and Neoplasia. 18: 253-5. PMID 24190309 DOI: 10.1007/s10911-013-9306-4 |
0.3 |
|
| 2013 |
Oesterreich S, Brufsky AM, Davidson NE. Using mice to treat (wo)men: mining genetic changes in patient xenografts to attack breast cancer. Cell Reports. 4: 1061-2. PMID 24075202 DOI: 10.1016/j.celrep.2013.09.008 |
0.318 |
|
| 2013 |
Jankowitz RC, McGuire KP, Davidson NE. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. Breast (Edinburgh, Scotland). 22: S165-70. PMID 24074781 DOI: 10.1016/j.breast.2013.07.032 |
0.338 |
|
| 2013 |
Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2870-8. PMID 23857972 DOI: 10.1200/Jco.2012.43.3391 |
0.341 |
|
| 2013 |
Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer. 119: 2675-82. PMID 23744760 DOI: 10.1002/cncr.28130 |
0.365 |
|
| 2013 |
Stearns V, Jacobs LK, Fackler M, Tsangaris TN, Rudek MA, Higgins M, Lange J, Cheng Z, Slater SA, Jeter SC, Powers P, Briest S, Chao C, Yoshizawa C, Sugar E, ... Davidson NE, et al. Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4008-16. PMID 23719261 DOI: 10.1158/1078-0432.Ccr-13-0033 |
0.332 |
|
| 2013 |
Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis. 34: 1196-207. PMID 23354309 DOI: 10.1093/carcin/bgt033 |
0.325 |
|
| 2013 |
McAuliffe PF, Danoff S, Shapiro SD, Davidson NE. Treatment for breast cancer: is time really of the essence? Journal of the National Cancer Institute. 105: 80-2. PMID 23264682 DOI: 10.1093/jnci/djs524 |
0.366 |
|
| 2013 |
Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 961-5. PMID 23129741 DOI: 10.1200/JCO.2012.45.9859 |
0.342 |
|
| 2013 |
Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 119: 1140-8. PMID 23065954 DOI: 10.1002/Cncr.27819 |
0.369 |
|
| 2013 |
Adams S, Gray R, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA, Badve S. Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O22 |
0.338 |
|
| 2013 |
Connolly RM, Jankowitz RC, Zahnow CA, Zhang Z, Rudek MA, Jeter SC, Slater S, Powers P, Wolff AC, Fetting J, Brufsky AM, Piekarz R, Ahuja N, Somlo G, Garcia A, ... ... Davidson NE, et al. Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer. Cancer Research. 73: 4666-4666. DOI: 10.1158/1538-7445.Am2013-4666 |
0.392 |
|
| 2013 |
Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L, Martino S, Davidson N, Sledge G, Sparano J, Badve S. Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-S1-07 |
0.373 |
|
| 2013 |
Wolff AC, Domchek SM, Davidson NE, Sacchini V, McCormick B. Cancer of the Breast Abeloff's Clinical Oncology: Fifth Edition. 1630-1692.e9. DOI: 10.1016/B978-1-4557-2865-7.00091-6 |
0.393 |
|
| 2012 |
Brewster AM, Davidson NE, McCaskill-Stevens W. Chemoprevention for breast cancer: overcoming barriers to treatment. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 85-90. PMID 24451714 DOI: 10.14694/EdBook_AM.2012.32.85 |
0.37 |
|
| 2012 |
Bhargava R, Brufsky AM, Davidson NE. Prognostic/Predictive immunohistochemistry assays for estrogen receptor-positive breast cancer: back to the future? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4451-3. PMID 23045595 DOI: 10.1200/JCO.2012.44.6955 |
0.349 |
|
| 2012 |
Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Fetting J, Davidson NE. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 118: 5937-46. PMID 22926690 DOI: 10.1002/Cncr.27527 |
0.308 |
|
| 2012 |
Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE, Sparano JA. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3051-7. PMID 22851566 DOI: 10.1200/Jco.2011.39.8446 |
0.337 |
|
| 2012 |
Sparano JA, Goldstein LJ, Davidson NE, Sledge GW, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 134: 751-7. PMID 22706628 DOI: 10.1007/s10549-012-2112-7 |
0.347 |
|
| 2012 |
Puhalla S, Bhattacharya S, Davidson NE. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. Molecular Oncology. 6: 222-36. PMID 22406404 DOI: 10.1016/j.molonc.2012.02.003 |
0.351 |
|
| 2012 |
Hu D, Zhou Z, Davidson NE, Huang Y, Wan Y. Novel insight into KLF4 proteolytic regulation in estrogen receptor signaling and breast carcinogenesis. The Journal of Biological Chemistry. 287: 13584-97. PMID 22389506 DOI: 10.1074/jbc.M112.343566 |
0.367 |
|
| 2012 |
Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, et al. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Research and Treatment. 131: 915-24. PMID 22076478 DOI: 10.1007/s10549-011-1858-7 |
0.374 |
|
| 2012 |
Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 131: 907-14. PMID 22042368 DOI: 10.1007/s10549-011-1843-1 |
0.329 |
|
| 2012 |
Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Wu X, Lobie PE, Davidson NE, Bhujwalla ZM, et al. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proceedings of the National Academy of Sciences of the United States of America. 109: 2736-41. PMID 21690342 DOI: 10.1073/Pnas.1018859108 |
0.317 |
|
| 2012 |
Romond E, Suman V, Jeong J, Sledge G, Geyer C, Martino S, Rastogi P, Gralow J, Swain S, Winer E, Colon-Otero G, Hudis C, Paik S, Davidson N, Mamounas E, et al. Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S5-5 |
0.384 |
|
| 2012 |
Jankowitz RC, Davidson NE. Breast Cancer Primary Prevention: ‘SERM-Mounting’ Existing Obstacles and Future Directions Breast Diseases: a Year Book Quarterly. 23: 19-23. DOI: 10.1016/J.BREASTDIS.2012.01.055 |
0.383 |
|
| 2011 |
Huang Y, Nayak S, Jankowitz R, Davidson NE, Oesterreich S. Epigenetics in breast cancer: what's new? Breast Cancer Research : Bcr. 13: 225. PMID 22078060 DOI: 10.1186/bcr2925 |
0.31 |
|
| 2011 |
Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, et al. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7194-203. PMID 21933890 DOI: 10.1158/1078-0432.CCR-10-3357 |
0.375 |
|
| 2011 |
Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, ... ... Davidson NE, et al. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prevention Research (Philadelphia, Pa.). 4: 1993-2001. PMID 21885816 DOI: 10.1158/1940-6207.Capr-11-0154 |
0.372 |
|
| 2011 |
Puhalla S, Jankowitz RC, Davidson NE. Adjuvant endocrine therapy for breast cancer: don't ditch the switch! Journal of the National Cancer Institute. 103: 1280-2. PMID 21859987 DOI: 10.1093/jnci/djr302 |
0.344 |
|
| 2011 |
Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3366-73. PMID 21768458 DOI: 10.1200/JCO.2011.35.0868 |
0.309 |
|
| 2011 |
Davidson NE, Kensler TW. "MAPping" the course of chemoprevention in breast cancer. The New England Journal of Medicine. 364: 2463-4. PMID 21639807 DOI: 10.1056/NEJMe1106052 |
0.343 |
|
| 2011 |
Connolly R, Jankowitz R, Andreopoulou E, Allred J, Jeter S, Zorzi J, Adam B, Espinoza-Delgado I, Baylin S, Zahnow C, Ahuja N, Davidson N, Stearns V. OT3-01-06: A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot3-01-06 |
0.351 |
|
| 2011 |
Lawrence LdS, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange J, Jacobs L, Emens L, Armstrong D, Fetting J, Garrett-Mayer E, Davidson N, Wolff A, et al. 750 poster COSMETIC OUTCOME AFTER PARTIAL BREAST IRRADIATION WITH CONCURRENT CHEMOTHERAPY IN EARLY-STAGE BREAST CANCER Radiotherapy and Oncology. 99. DOI: 10.1016/S0167-8140(11)70872-6 |
0.366 |
|
| 2011 |
Davidson N. Breast Cancer and Benign Breast Disorders Goldman's Cecil Medicine: Twenty Fourth Edition. 1: 1309-1317. DOI: 10.1016/B978-1-4377-1604-7.00204-9 |
0.362 |
|
| 2010 |
Rastogi P, Davidson NE. Trastuzumab as single agent therapy for HER2-positive metastatic breast cancer. Onkologie. 33: 420-1. PMID 20838056 DOI: 10.1159/000318991 |
0.371 |
|
| 2010 |
Oesterreich S, Lee AV, Davidson NE. Is it time to ReSET the standard for estrogen receptor testing in breast cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4101-3. PMID 20697070 DOI: 10.1200/JCO.2010.30.9864 |
0.35 |
|
| 2010 |
Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3784-96. PMID 20625130 DOI: 10.1200/Jco.2009.26.3756 |
0.372 |
|
| 2010 |
Yao Y, Brodie AM, Davidson NE, Kensler TW, Zhou Q. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Research and Treatment. 124: 585-91. PMID 20623181 DOI: 10.1007/s10549-010-1023-8 |
0.312 |
|
| 2010 |
Stearns V, Jacobs LK, Tsangaris TN, Cheng Z, Slater S, Fackler MJ, Chao C, Bugarini R, Gabrielson E, Davidson NE. Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer. Journal of Clinical Oncology. 28: 3097-3097. DOI: 10.1200/JCO.2010.28.15_SUPPL.3097 |
0.304 |
|
| 2010 |
Shaw PG, Chearkady R, Pandey A, Davidson N. Abstract 3648: Proteomic profiling of vorinostat in breast cancer Cancer Research. 70: 3648-3648. DOI: 10.1158/1538-7445.Am10-3648 |
0.387 |
|
| 2010 |
Reinholz M, Dueck A, Wiktor A, Lingle W, Jenkins R, Davidson N, Martino S, Kaufman P, Kutteh L, Sledge G, Harris L, Gralow J, Geiger X, Perez E. Abstract P2-09-08: c-MYC (MYC) Protein Expression and Associations with Trastuzumab Benefit in Early-Stage, HER2+ Breast Cancer in Context of the NCCTG Adjuvant Trial, N9831 Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-09-08 |
0.316 |
|
| 2010 |
Zhou Q, Chaerkady R, Shaw PG, Kensler TW, Pandey A, Davidson NE. Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells Proteomics - Clinical Applications. 4: 757-757. DOI: 10.1002/prca.201090037 |
0.323 |
|
| 2009 |
Stearns V, Jacobs LK, Tsangaris TN, Briest S, Lange JR, Slater S, Fackler M, Sugar E, Gabrielson E, Davidson NE. A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14508. PMID 27963537 DOI: 10.1200/jco.2009.27.15_suppl.e14508 |
0.374 |
|
| 2009 |
Sparano JA, Goldestin LJ, Childs BH, Shak S, Badve S, Baehner FL, Davidson NE, Sledge GW, Gray R. Genotypic characterization of phenotypically defined triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 500. PMID 27960782 DOI: 10.1200/jco.2009.27.15_suppl.500 |
0.375 |
|
| 2009 |
Sukov WR, Miller DV, Dueck AC, Tenner KS, Jenkins RB, Kaufman PA, Davidson NE, Dakhil SR, Martino S, Roy V, Perez EA. Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 520. PMID 27960675 DOI: 10.1200/Jco.2009.27.15_Suppl.520 |
0.332 |
|
| 2009 |
Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7693-7700. PMID 19996222 DOI: 10.1158/1078-0432.CCR-09-1450 |
0.338 |
|
| 2009 |
Puhalla S, Brufsky A, Davidson N. Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast (Edinburgh, Scotland). 18: S122-30. PMID 19914530 DOI: 10.1016/S0960-9776(09)70286-3 |
0.346 |
|
| 2009 |
Emens LA, Davidson NE. Postoperative endocrine therapy for invasive breast cancer. Cancer Treatment and Research. 151: 139-61. PMID 19593511 DOI: 10.1007/978-0-387-75115-3_10 |
0.377 |
|
| 2009 |
Chivukula M, Brufsky A, Davidson NE. Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer. Journal of the National Cancer Institute. 101: 698-9. PMID 19436037 DOI: 10.1093/jnci/djp098 |
0.366 |
|
| 2009 |
Billam M, Witt AE, Davidson NE. The silent estrogen receptor--can we make it speak? Cancer Biology & Therapy. 8: 485-96. PMID 19411863 DOI: 10.4161/Cbt.8.6.7582 |
0.388 |
|
| 2009 |
Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens LA, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, Wolff AC. Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2816-22. PMID 19332718 DOI: 10.1200/Jco.2008.20.0139 |
0.362 |
|
| 2009 |
Higgins MJ, Davidson NE. What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? Current Oncology Reports. 11: 45-50. PMID 19080741 DOI: 10.1007/S11912-009-0008-4 |
0.301 |
|
| 2009 |
Zhou Q, Shaw PG, Davidson NE. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Research and Treatment. 117: 443-51. PMID 18683042 DOI: 10.1007/s10549-008-0148-5 |
0.309 |
|
| 2009 |
Carraway HE, Wang S, Blackford A, Guo M, Powers P, Jeter S, Davidson NE, Argani P, Terrell K, Herman JG, Lange JR. Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence. Breast Cancer Research and Treatment. 114: 315-25. PMID 18404369 DOI: 10.1007/s10549-008-0004-7 |
0.311 |
|
| 2009 |
Perez E, Reinholz M, Dueck A, Wiktor A, Lingle W, Davidson N, Martino S, Kaufman P, Kutteh L, Jenkins R. c-MYC amplification and correlation with patient outcome in early stage HER2+ breast cancer from the NCCTG adjuvant intergroup trial N9831. Cancer Research. 69: 56. DOI: 10.1158/0008-5472.Sabcs-56 |
0.308 |
|
| 2009 |
Sparano J, Gray R, Goldstein L, Childs B, Bugarini R, Rowley S, Baker J, Shak S, Badve S, Baehner F, Perez E, Shulman L, Martino S, Sledge G, Davidson N. GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer. Cancer Research. 69: 25. DOI: 10.1158/0008-5472.Sabcs-25 |
0.343 |
|
| 2009 |
Brewster A, Davidson N, Rosenfeld JA. Breast cancer screening Handbook of Women's Health, Second Edition. 215-220. DOI: 10.1017/CBO9780511642111.020 |
0.391 |
|
| 2008 |
Moreno-Aspitia A, Dueck AC, Lingle WL, Kutteh L, Tenner K, Davidson NE, Martino S, Kaufman P, Carney WP, Perez EA. Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): Results from the NCCTG adjuvant Intergroup trial N9831. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 529. PMID 27948523 DOI: 10.1200/jco.2008.26.15_suppl.529 |
0.365 |
|
| 2008 |
Bao T, Davidson NE. Gene expression profiling of breast cancer. Advances in Surgery. 42: 249-60. PMID 18953822 DOI: 10.1016/j.yasu.2008.03.002 |
0.358 |
|
| 2008 |
Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6277-83. PMID 18829509 DOI: 10.1158/1078-0432.Ccr-08-0482 |
0.337 |
|
| 2008 |
Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4063-71. PMID 18678838 DOI: 10.1200/JCO.2007.14.4501 |
0.335 |
|
| 2008 |
Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4092-9. PMID 18678836 DOI: 10.1200/JCO.2008.16.7841 |
0.397 |
|
| 2008 |
Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. The New England Journal of Medicine. 358: 1663-71. PMID 18420499 DOI: 10.1056/Nejmoa0707056 |
0.336 |
|
| 2008 |
Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1938-46. PMID 18381931 DOI: 10.1158/1078-0432.Ccr-07-4082 |
0.348 |
|
| 2008 |
Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1231-8. PMID 18250349 DOI: 10.1200/JCO.2007.13.5467 |
0.332 |
|
| 2008 |
Briest S, Davidson NE. Aromatase inhibitors for breast cancer. Reviews in Endocrine & Metabolic Disorders. 8: 215-28. PMID 17486453 DOI: 10.1007/s11154-007-9039-z |
0.397 |
|
| 2008 |
Prowell TM, Fackler M, Argani P, Khouri NF, Blackford AL, Shahverdi K, Wolff AC, Davidson NE, Sukumar S, Stearns V. A prospective study of adjuvant anastrozole and gene promoter methylation in the contralateral breast of high-risk women Journal of Clinical Oncology. 26: 1514-1514. DOI: 10.1200/Jco.2008.26.15_Suppl.1514 |
0.401 |
|
| 2007 |
Bao T, Davidson NE. Adjuvant endocrine therapy for premenopausal women with early breast cancer. Breast Cancer Research : Bcr. 9: 115. PMID 18190722 DOI: 10.1186/bcr1830 |
0.302 |
|
| 2007 |
Stearns V, Zhou Q, Davidson NE. Epigenetic regulation as a new target for breast cancer therapy. Cancer Investigation. 25: 659-65. PMID 18058459 DOI: 10.1080/07357900701719234 |
0.355 |
|
| 2007 |
Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Research. 67: 5337-44. PMID 17545614 DOI: 10.1158/0008-5472.Can-06-4582 |
0.312 |
|
| 2007 |
Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Molecular Cancer Therapeutics. 6: 1013-21. PMID 17339367 DOI: 10.1158/1535-7163.MCT-06-0494 |
0.308 |
|
| 2007 |
Stebbing J, Stearns V, Davidson NE. Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. Pharmacogenomics. 8: 1-3. PMID 17187500 DOI: 10.2217/14622416.8.1.1 |
0.36 |
|
| 2007 |
Perez EA, Romond EH, Suman VJ, Jeong J, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kauffman PA, Wolmark N, Ncctg, Nsabp. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer Journal of Clinical Oncology. 25: 512-512. DOI: 10.1200/Jco.2007.25.18_Suppl.512 |
0.337 |
|
| 2006 |
Brown RJ, Davidson NE. Adjuvant hormonal therapy for premenopausal women with breast cancer. Seminars in Oncology. 33: 657-63. PMID 17145345 DOI: 10.1053/J.SEMINONCOL.2006.08.014 |
0.316 |
|
| 2006 |
Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Investigation. 24: 677-81. PMID 17118777 DOI: 10.1080/07357900600981349 |
0.342 |
|
| 2006 |
Wolff AC, Davidson NE. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4949-51. PMID 17075110 DOI: 10.1200/JCO.2006.07.9160 |
0.353 |
|
| 2006 |
Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg F, Somerfield MR, Davidson NE. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5091-7. PMID 17033037 DOI: 10.1200/JCO.2006.08.8575 |
0.316 |
|
| 2006 |
Zhou Q, Davidson NE. Silencing estrogen receptor alpha in breast cancer cells. Cancer Biology & Therapy. 5: 848-9. PMID 16921265 DOI: 10.4161/cbt.5.7.3205 |
0.325 |
|
| 2006 |
Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Research. 66: 6370-8. PMID 16778215 DOI: 10.1158/0008-5472.Can-06-0402 |
0.351 |
|
| 2006 |
Wolff AC, Jones RJ, Davidson NE, Jeter SC, Stearns V. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2392-4; author reply. PMID 16710041 DOI: 10.1200/JCO.2006.05.7174 |
0.378 |
|
| 2006 |
Huang Y, Keen JC, Pledgie A, Marton LJ, Zhu T, Sukumar S, Park BH, Blair B, Brenner K, Casero RA, Davidson NE. Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells. The Journal of Biological Chemistry. 281: 19055-63. PMID 16679312 DOI: 10.1074/Jbc.M600910200 |
0.315 |
|
| 2006 |
Abukhdeir AM, Blair BG, Brenner K, Karakas B, Konishi H, Lim J, Sahasranaman V, Huang Y, Keen J, Davidson N, Vitolo MI, Bachman KE, Park BH. Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Research and Treatment. 99: 23-33. PMID 16541319 DOI: 10.1007/S10549-006-9177-0 |
0.304 |
|
| 2006 |
Modzelewska A, Pettit C, Achanta G, Davidson NE, Huang P, Khan SR. Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorganic & Medicinal Chemistry. 14: 3491-5. PMID 16434201 DOI: 10.1016/j.bmc.2006.01.003 |
0.329 |
|
| 2006 |
Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. The New England Journal of Medicine. 354: 270-82. PMID 16421368 DOI: 10.1056/NEJMRA050776 |
0.398 |
|
| 2006 |
Perez E, Halyard M, Pisansky T, Suman V, Dueck A, Davidson N, Martino S, Kaufman P. Radiotherapy concurrent with trastuzumab is well tolerated in the adjuvant treatment of women with HER2-positive breast cancer: cardiac safety data from the NCCTG N9831 study European Journal of Cancer Supplements. 4: 113. DOI: 10.1016/S1359-6349(06)80248-X |
0.33 |
|
| 2005 |
Wolff AC, O'Neill A, Kennedy MJ, Stewart JA, Gradishar WJ, Lord RS, Davidson NE, Wood WC. Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193. Clinical Breast Cancer. 6: 334-9. PMID 16277884 DOI: 10.3816/CBC.2005.n.037 |
0.352 |
|
| 2005 |
Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, Davidson NE, Fung ET, Chan DW. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clinical Chemistry. 51: 2229-35. PMID 16223889 DOI: 10.1373/clinchem.2005.052878 |
0.313 |
|
| 2005 |
Davidson NE, Sukumar S. Of Snail, mice, and women. Cancer Cell. 8: 173-174. PMID 16169460 DOI: 10.1016/J.Ccr.2005.08.006 |
0.365 |
|
| 2005 |
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute. 97: 1262-71. PMID 16145047 DOI: 10.1093/Jnci/Dji250 |
0.317 |
|
| 2005 |
Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5973-82. PMID 16087950 DOI: 10.1200/JCO.2005.05.551 |
0.354 |
|
| 2005 |
Davidson NE, Morrow M. Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer. Journal of the National Cancer Institute. 97: 159-61. PMID 15687353 DOI: 10.1093/JNCI/DJI049 |
0.36 |
|
| 2005 |
Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4683-90. PMID 15570070 DOI: 10.1200/JCO.2004.08.054 |
0.33 |
|
| 2005 |
Prowell TM, Davidson NE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? The Oncologist. 9: 507-17. PMID 15477635 DOI: 10.1634/THEONCOLOGIST.9-5-507 |
0.387 |
|
| 2005 |
Davidson N. The challenges in translating present knowledge of the molecular biology of breast cancer into clinical use Breast Cancer Research. 7: 1-1. DOI: 10.1186/Bcr1044 |
0.333 |
|
| 2004 |
Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 567. PMID 28016470 DOI: 10.1200/Jco.2004.22.14_Suppl.567 |
0.305 |
|
| 2004 |
Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3700-4. PMID 15365066 DOI: 10.1200/JCO.2004.03.516 |
0.347 |
|
| 2004 |
Gabrielson E, Tully E, Hacker A, Pegg AE, Davidson NE, Casero RA. Induction of spermidine/spermine N1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N1, N11-diethylnorspermine. Cancer Chemotherapy and Pharmacology. 54: 122-6. PMID 15138709 DOI: 10.1007/S00280-004-0786-1 |
0.307 |
|
| 2004 |
Stearns V, Davidson NE. Déjà vu for breast cancer two? Journal of the National Cancer Institute. 96: 497-9. PMID 15069104 DOI: 10.1093/JNCI/DJH119 |
0.393 |
|
| 2004 |
Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. The Pharmacogenomics Journal. 4: 143-53. PMID 15024382 DOI: 10.1038/sj.tpj.6500242 |
0.377 |
|
| 2004 |
Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biology & Therapy. 2: 552-6. PMID 14614325 DOI: 10.4161/cbt.2.5.469 |
0.302 |
|
| 2004 |
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, et al. A Randomized Trial of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer Obstetrical & Gynecological Survey. 59: 201-203. DOI: 10.1097/01.OGX.0000115858.45890.53 |
0.338 |
|
| 2003 |
Davidson NE, Visvanathan K, Emens L. New findings about endocrine therapy for breast cancer. Breast (Edinburgh, Scotland). 12: 368-72. PMID 14659107 DOI: 10.1016/S0960-9776(03)00138-3 |
0.333 |
|
| 2003 |
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. The New England Journal of Medicine. 349: 1793-802. PMID 14551341 DOI: 10.1056/Nejmoa032312 |
0.318 |
|
| 2003 |
Emens LA, Davidson NE. The follow-up of breast cancer. Seminars in Oncology. 30: 338-48. PMID 12870135 DOI: 10.1016/S0093-7754(03)00094-0 |
0.391 |
|
| 2003 |
Kumar SK, Hager E, Pettit C, Gurulingappa H, Davidson NE, Khan SR. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. Journal of Medicinal Chemistry. 46: 2813-5. PMID 12825923 DOI: 10.1021/JM030213+ |
0.361 |
|
| 2003 |
Visvanathan K, Davidson NE. Aromatase inhibitors as adjuvant therapy in breast cancer. Oncology (Williston Park, N.Y.). 17: 335-42, 347; discuss. PMID 12661266 |
0.397 |
|
| 2003 |
Davidson NE. Ongoing US cooperative group trials using taxanes in the adjuvant setting. Clinical Breast Cancer. S53-8. PMID 12435293 DOI: 10.3816/CBC.2002.S.012 |
0.381 |
|
| 2003 |
Pierce LJ, Lew D, Hutchins L, Davidson N, Albain K, Fetting J, Solin L. Patterns of recurrence by sequence of chemotherapy and radiotherapy in early stage breast cancer International Journal of Radiation Oncology Biology Physics. 57. DOI: 10.1016/S0360-3016(03)00828-9 |
0.321 |
|
| 2002 |
Davidson NE, Helzlsouer KJ. Good news about oral contraceptives New England Journal of Medicine. 346: 2078-2079. PMID 12087145 DOI: 10.1056/Nejme020051 |
0.331 |
|
| 2002 |
Wolff AC, Davidson NE. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. The Oncologist. 7: 239-45. PMID 12065797 DOI: 10.1634/THEONCOLOGIST.7-3-239 |
0.317 |
|
| 2002 |
Wolff AC, Davidson NE. Early operable breast cancer. Current Treatment Options in Oncology. 1: 210-20. PMID 12057163 DOI: 10.1007/S11864-000-0032-Y |
0.38 |
|
| 2002 |
Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. Journal of the National Cancer Institute. 94: 855-7. PMID 12048274 DOI: 10.1093/Jnci/94.11.855 |
0.317 |
|
| 2002 |
Davidson NE, Levine M. Breast cancer consensus meetings: vive la difference? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1719-20. PMID 11919226 DOI: 10.1200/JCO.2002.20.7.1719 |
0.384 |
|
| 2002 |
Wolff AC, Davidson NE. Use of SERMs for the adjuvant therapy of early-stage breast cancer. Annals of the New York Academy of Sciences. 949: 80-8. PMID 11795384 DOI: 10.1111/j.1749-6632.2001.tb04005.x |
0.394 |
|
| 2001 |
Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer Journal of the National Cancer Institute. Monographs. 67-71. PMID 11773295 DOI: 10.1093/OXFORDJOURNALS.JNCIMONOGRAPHS.A003464 |
0.386 |
|
| 2001 |
Dees EC, Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. Seminars in Oncology. 28: 322-31. PMID 11498826 DOI: 10.1016/S0093-7754(01)90126-5 |
0.375 |
|
| 2001 |
Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 3357-66. PMID 11454883 DOI: 10.1200/JCO.2001.19.14.3357 |
0.332 |
|
| 2001 |
Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocrine-Related Cancer. 8: 115-27. PMID 11446343 DOI: 10.1677/ERC.0.0080115 |
0.334 |
|
| 2001 |
Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung BM, Davidson NE, Sukumar S. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR The Lancet. 357: 1335-1336. PMID 11343741 DOI: 10.1016/S0140-6736(00)04501-3 |
0.326 |
|
| 2001 |
Wolff AC, Davidson NE. New data on adjuvant therapy for breast cancer. Current Oncology Reports. 1: 31-7. PMID 11122795 DOI: 10.1007/S11912-999-0007-5 |
0.359 |
|
| 2001 |
Davidson N, Wolff A. The use of anthracyclines and taxanes for adjuvant therapy of breast cancer The Breast. 10: 90-95. DOI: 10.1016/S0960-9776(16)30016-9 |
0.385 |
|
| 2001 |
Hornby L, Davidson N, Houghton D. Metastatic breast cancer: a patient friendly approach with a new drug therapy European Journal of Cancer. 37: S431. DOI: 10.1016/S0959-8049(01)82048-7 |
0.339 |
|
| 2000 |
van der Wall E, Horn T, Bright E, Passos-Coehlo JL, Bond S, Clarke B, Altomonte V, McIntyre K, Vogelsang G, Noga SJ, Davis JM, Thomassen J, Ohly KV, Lee SM, Fetting J, ... ... Davidson NE, et al. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. British Journal of Cancer. 83: 1405-11. PMID 11076645 DOI: 10.1054/bjoc.2000.1499 |
0.316 |
|
| 2000 |
Davidson NE. Combined endocrine therapy for breast cancer - New life for an old idea? Journal of the National Cancer Institute. 92: 859-860. PMID 10841814 |
0.354 |
|
| 2000 |
Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 1558-69. PMID 10735905 DOI: 10.1200/JCO.2000.18.7.1558 |
0.33 |
|
| 1999 |
Nass SJ, Davidson NE. The biology of breast cancer. Hematology/Oncology Clinics of North America. 13: 311-32. PMID 10363133 DOI: 10.1016/S0889-8588(05)70058-7 |
0.359 |
|
| 1999 |
Subramanyan S, Abeloff MD, Bond SE, Davidson NE, Fetting JH, Gordon GB, Kennedy MJ. A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 43: 497-502. PMID 10321510 DOI: 10.1007/s002800050929 |
0.372 |
|
| 1999 |
Smith TJ, Davidson NE, Schapira DV, Grunfeld E, Muss HB, Vogel VG, Somerfield MR. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1080-2. PMID 10071303 DOI: 10.1200/JCO.1999.17.3.1080 |
0.304 |
|
| 1998 |
Lapidus RG, Nass SJ, Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. Journal of Mammary Gland Biology and Neoplasia. 3: 85-94. PMID 10819507 DOI: 10.1023/A:1018778403001 |
0.364 |
|
| 1998 |
Davidson NE. Environmental estrogens and breast cancer risk. Current Opinion in Oncology. 10: 475-8. PMID 9800120 DOI: 10.1097/00001622-199809000-00018 |
0.37 |
|
| 1998 |
Nass SJ, Hahm HA, Davidson NE. Breast cancer biology blossoms in the clinic. Nature Medicine. 4: 761-2. PMID 9662357 DOI: 10.1038/nm0798-761 |
0.38 |
|
| 1998 |
Hahm HA, Davidson NE, Giguere JK, DiBernardo C, O'Reilly S. Breast cancer metastatic to the choroid Journal of Clinical Oncology. 16: 2280-2282. PMID 9626232 DOI: 10.1200/JCO.1998.16.6.2280 |
0.396 |
|
| 1998 |
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, Yoshida M, van de Velde AO, van Dongen JA, Vermorken JB, Giokas G, ... ... Davidson NE, et al. Tamoxifen for early breast cancer: An overview of the randomised trials Lancet. 351: 1451-1467. PMID 9605801 DOI: 10.1016/S0140-6736(97)11423-4 |
0.321 |
|
| 1998 |
Ferguson AT, Lapidus RG, Davidson NE. The regulation of estrogen receptor expression and function in human breast cancer. Cancer Treatment and Research. 94: 255-78. PMID 9587692 DOI: 10.1007/978-1-4615-6189-7_14 |
0.342 |
|
| 1998 |
Ferguson AT, Davidson NE. Regulation of estrogen receptor alpha function in breast cancer. Critical Reviews in Oncogenesis. 8: 29-46. PMID 9516085 DOI: 10.1615/CRITREVONCOG.V8.I1.20 |
0.358 |
|
| 1998 |
Hahm HA, Davidson NE. Apoptosis in the mammary gland and breast cancer Endocrine-Related Cancer. 5: 199-211. DOI: 10.1677/erc.0.0050199 |
0.373 |
|
| 1998 |
Davidson N, Wood J, Treves J, Snooks S. Primary chemotherapy for locally advanced breast cancer using film as a novel regimen European Journal of Cancer. 34: S13. DOI: 10.1016/S0959-8049(98)80044-0 |
0.327 |
|
| 1997 |
Davidson NE, Yager JD. Pesticides and breast cancer: fact or fad? Journal of the National Cancer Institute. 89: 1743-4. PMID 9392608 DOI: 10.1093/JNCI/89.23.1743 |
0.393 |
|
| 1997 |
Dees EC, Davidson NE. Management of Early Stage Breast Cancer Disease Management & Health Outcomes. 2: 270-280. DOI: 10.2165/00115677-199702060-00002 |
0.322 |
|
| 1996 |
Ross AA, Layton TJ, Ostrander AB, Passos-Coelho JL, Davis JM, Huelskamp AM, Noga SJ, Davidson NE, Kennedy MJ, Cooper BW, Gerson SL, Lazarus HM, Holland K, Gluck S, Moss TJ, et al. Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. Journal of Hematotherapy. 5: 549-52. PMID 8938527 |
0.334 |
|
| 1995 |
Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. Journal of the National Cancer Institute. 87: 1254-6. PMID 7563172 DOI: 10.1093/JNCI/87.16.1254 |
0.359 |
|
| 1995 |
Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC. Estrogen Replacement Therapy in Breast Cancer Survivors The Endocrinologist. 5: 82. DOI: 10.1097/00019616-199501000-00018 |
0.388 |
|
| 1994 |
Davidson NE, Abeloff MD. Adjuvant therapy of breast cancer. World Journal of Surgery. 18: 112-6. PMID 8197765 DOI: 10.1007/BF00348200 |
0.383 |
|
| 1994 |
Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC. Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change Jama: the Journal of the American Medical Association. 272: 540-545. DOI: 10.1001/jama.1994.03520070060039 |
0.389 |
|
| 1993 |
Davidson NE, Abeloff MD. Menstrual effects on surgical treatment for breast cancer. Cancer Treatment Reviews. 19: 105-12. PMID 8481925 DOI: 10.1016/0305-7372(93)90029-Q |
0.361 |
|
| 1993 |
Davidson NE. Biology of breast cancer and its clinical implications. Current Opinion in Oncology. 4: 1003-9. PMID 1457515 DOI: 10.1097/00001622-199212000-00002 |
0.398 |
|
| 1992 |
Davidson NE, Abeloff MD. Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse. Journal of the National Cancer Institute. 84: 301-5. PMID 1531367 DOI: 10.1093/JNCI/84.5.301 |
0.323 |
|
| 1991 |
Davidson NE. Biology and prognostic factors of breast cancer. Current Opinion in Oncology. 2: 1025-30. PMID 1983088 DOI: 10.1097/00001622-199012000-00003 |
0.372 |
|
| 1991 |
Davidson NE. Biology of breast cancer Current Opinion in Oncology. 3: 988-994. PMID 1843117 |
0.393 |
|
| 1989 |
Geller RB, Boone LB, Karp JHE, Davidson N, Selonick SE, Edwards J, Burke PJ. Secondary acute myelocytic leukemia after adjuvant therapy for early-stage breast carcinoma. A new complication of cyclophosphamide, methotrexate, and 5-fluorouracil therapy. Cancer. 64: 629-634. PMID 2743258 DOI: 10.1002/1097-0142(19890801)64:3<629::Aid-Cncr2820640311>3.0.Co;2-L |
0.371 |
|
| 1987 |
Davidson NE, Lippman ME. Stimulation of breast cancer with estrogens: how much clinical value? European Journal of Cancer & Clinical Oncology. 23: 897-900. PMID 3311768 DOI: 10.1016/0277-5379(87)90332-4 |
0.353 |
|
| 1986 |
Davidson NE, Lippman ME. Combined therapy in advanced breast cancer. European Journal of Cancer & Clinical Oncology. 21: 1123-6. PMID 3000786 DOI: 10.1016/0277-5379(85)90002-1 |
0.387 |
|
| 1986 |
Kasid A, Davidson NE, Gelmann EP, Lippman ME. Transcriptional control of thymidine kinase gene expression by estrogen and antiestrogens in MCF-7 human breast cancer cells. Journal of Biological Chemistry. 261: 5562-5567. DOI: 10.1016/s0021-9258(19)57251-9 |
0.33 |
|
| Show low-probability matches. |